Following a full submission
bortezomib (Velcade) is not recommended for use within NHS Scotland as mono-therapy for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.
Bortezomib, compared to high dose dexamethasone, prolonged time to disease progression by 2.7 months and improved survival in patients who had progressive multiple myeloma despite previous treatment with one to three lines of therapy. However, the economic case has not been demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice53KB (PDF)
- Medicine name:
- bortezomib (Velcade) 3.5mg powder for intravenous injection
- SMC ID:
- Multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation
- Pharmaceutical company
- Ortho Biotech
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Not recommended
- Date advice published
- 11 September 2006